AZD0022, AZD0022, Erbitux 5 mg/mL solution for infusion clinical trials

A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)

This study looks at a new drug, AZD0022, for people with certain types of lung, bowel, and pancreatic cancer. Doctors want to see if it's safe, how the body handles it, and if it can help shrink tumours, both on its own and with other cancer drugs.